{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:27:02Z","timestamp":1781756822197,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ijrobp.2011.04.026","type":"journal-article","created":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T20:20:15Z","timestamp":1308601215000},"page":"e385-e392","source":"Crossref","is-referenced-by-count":41,"title":["Comparison of Prophylactic Naftopidil, Tamsulosin, and Silodosin for 125I Brachytherapy\u2013Induced Lower Urinary Tract Symptoms in Patients With Prostate Cancer: Randomized Controlled Trial"],"prefix":"10.1016","volume":"81","author":[{"given":"Hideyasu","family":"Tsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouko","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Minamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2011.04.026_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0360-3016(01)02812-7","article-title":"Predictive factors of urinary retention following prostate brachytherapy","volume":"53","author":"Bucci","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.urology.2006.08.1093","article-title":"Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: A prospective longitudinal study","volume":"68","author":"Namiki","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1464-410X.2007.07016.x","article-title":"Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: Analysis at > or\u00a0= 7 years of follow-up","volume":"100","author":"Cesaretti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.1996.14.2.449","article-title":"Tumor control and morbidity following transperineal iodine 125 implantation for stage T1\/T2 prostatic carcinoma","volume":"14","author":"Wallner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0022-5347(01)62542-4","article-title":"Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate","volume":"160","author":"Terk","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.1999.17.2.517","article-title":"Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer","volume":"17","author":"Zelefsky","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0360-3016(99)00525-8","article-title":"Temporal resolution of urinary morbidity following prostate brachytherapy","volume":"47","author":"Merrick","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(01)01530-9","article-title":"Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method","volume":"50","author":"Kang","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0360-3016(01)02657-8","article-title":"Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study","volume":"52","author":"Locke","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0090-4295(02)02142-8","article-title":"Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy","volume":"61","author":"Elshaikh","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0090-4295(02)01840-X","article-title":"Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy","volume":"60","author":"Merrick","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1464-410X.2005.05346.x","article-title":"Brachytherapy-related dysuria","volume":"95","author":"Merrick","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2004.09.036","article-title":"Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study","volume":"62","author":"Elshaikh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib14","first-page":"1315","article-title":"Dose-dependent effects and clinical usefulness of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hyperplasia\u2014double-blind comparative study compared with placebo","volume":"31","author":"Yamaguchi","year":"1997","journal-title":"Kiso Rinsho"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0022-5347(17)39620-9","article-title":"Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group","volume":"144","author":"Kawabe","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","article-title":"Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men","volume":"98","author":"Kawabe","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jjco\/hyn053","article-title":"Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer","volume":"38","author":"Ishiyama","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.radonc.2005.12.008","article-title":"Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer","volume":"78","author":"Ishiyama","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1118\/1.1646040","article-title":"Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations","volume":"31","author":"Rivard","year":"2004","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0360-3016(02)02786-4","article-title":"The Anderson nomograms for permanent interstitial prostate implants: A briefing for practitioners","volume":"53","author":"Cohen","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2008.07.001","article-title":"Inter-software variability in post-implanted CT analysis for interstitial permanent brachytherapy for prostate cancer: Differences in automatically detected seed location","volume":"89","author":"Ishiyama","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1464-410X.2005.05688.x","article-title":"Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial","volume":"96","author":"Gotoh","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib23","article-title":"Complications of permanent interstitial brachytherapy for carcinoma of the prostate","volume":"23","author":"Miller","year":"2004","journal-title":"AUA Update Series"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00171338","article-title":"Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor","volume":"348","author":"Michel","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1254\/jjp.79.447","article-title":"Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors","volume":"79","author":"Takei","year":"1999","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2007.10.082","article-title":"Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia","volume":"179","author":"Kojima","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib27","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.juro.2009.08.030","article-title":"Efficacy of silodosin for relieving benign prostatic obstruction: Prospective pressure flow study","volume":"182","author":"Matsukawa","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0022-5347(05)67426-5","article-title":"Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature","volume":"164","author":"Murata","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-5347(17)35544-1","article-title":"Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate","volume":"150","author":"Price","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1476-5381.1996.tb15742.x","article-title":"Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue","volume":"119","author":"Nasu","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2011.04.026_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410X.1998.0810s1048.x","article-title":"Current status of research on prostate-selective alpha 1-antagonists","volume":"81","author":"Kawabe","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.urology.2008.07.032","article-title":"Effect of naftopidil on nocturia after failure of tamsulosin","volume":"72","author":"Oh-oka","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1442-2042.2003.00712.x","article-title":"Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two-drug crossover study","volume":"10","author":"Ikemoto","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.ijrobp.2011.04.026_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10147-008-0799-6","article-title":"Interactive-plan technique conquers the disadvantages of volume-reducing hormone therapy in 125I permanent implantation for localized prostate cancer","volume":"14","author":"Ishiyama","year":"2009","journal-title":"Int J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301611005475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301611005475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T22:30:21Z","timestamp":1560292221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301611005475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0360301611005475"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.04.026","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}